Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The results are not all of a sudden change, they'll all be good. Looking forward to seeing how everything works out, no stress regarding this share just let the shareprice do it's thing in the meantime.!
Nolupus. Astra Zenica signed a deal with RedX today. I am not interested in RedX, but the deal was for research and further development of their treatment. Not covik related treatment. I find this encouraging as it adds good argument for partnership, whom ever that might be.
Atb
Nolupus,
I'll take that :)
STIm,
We might get the partnership news alongside the COPD interim results ....
Wait and see
100 HOSPITALISED patients in its clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients has now been completed.
Yes, that's hospitalised trials for which we have received the results.
Home trial results won't be any time soon due to uptake I reckon.
Biggest bits of news due imminently are COPD results, verification of hospitalised total results... Hopefully regulatory shortly afterwards and any JV/take over RNS.
Unless im reading the may RNS wrong
Recruitment of Patients in SG016 Trial Completed
Thu, 28th May 2020 07:00
RNS Number : 1327O
Synairgen plc
28 May 2020
Press release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial
Southampton, UK - 28 May 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that recruitment of 100 hospitalised patients in its clinical trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients has now been completed.
The COVID-19 study
Synairgen's clinical trial in COVID-19 patients (SG016) is a double-blind, placebo-controlled trial. The 220 patient trial comprises 100 patients initiated in hospital and 120 patients initiated in the home setting. The patients participating in the hospital setting have been recruited across a number of NHS trusts and the trial has been adopted by the NIHR Respiratory Translational Research Collaboration which is comprised of leading centres in respiratory medicine in the UK whose internationally recognised experts are working together to accelerate development and discovery for COVID-19. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients. Results from the hospital setting are expected in July 2020, as announced in the Company's Preliminary Results statement on 26 May 2020.
Recruitment for the home patients isn't complete - where did you hear this?
Are you getting confused with the hostpitalised trials?
If the trial is for 14 days of the Inhaler and the recruitment of the 120 patients (home) completed in May (RNS on Thu, 28th May 2020), then the last patient would have completed the trial by the 12th of June. The outputs of Home Trialing is surely due to land?
Many thanks Phil, very informative.
jint
HOME TRIAL INFO
If the test shows that you are infected with coronavirus, you will be randomly put into one of two treatment groups: one group will be given SNG001 and the other group will be given a placebo (a ‘dummy treatment’, which looks like the trial medicine but does not contain Interferon-ß). If the test is negative a trial nurse will let you know, and you will not be able to enter the trial.
The trial medication will be administered as an aerosol via a handheld nebuliser. The trial nurse will train you on how to take the trial medication via video call. You will take a dose of trial medication once a day for 14 days.
A trial doctor or nurse will contact you once a day, via video call, to help you with taking the trial medication. They will also ask you questions about how you are feeling, and help you to measure your pulse, oxygen levels and temperature using simple equipment that will be provided to you.
The day after your final treatment dose, you will have another video call with a trial doctor or nurse and be asked questions about your response to treatment, including assessing any side effects. Two weeks after your final treatment dose, you will have your final video call with a trial doctor or nurse and be asked questions about how you are feeling.
Sorry sng001
Will the home trial syn001 be administered X times a day by a professional ie nurse?
Some great debating today ....... thankyou and gla !!
Rockersdrift,
The powering of the trial would be of some concern that's for sure ...
109 instead of 120 is a big difference ...
Another concern I would have would be the placebo effect on the home trial patients given the high level of publicity surrounding SNG after the hospital patients results but we will just have to wait and see ...
BUg
Some inclination :-)
Hi Nolupus I am not sure if 'asile inclinaisons' is a technical term!
Hi Rorkes, although the grounds for the permission of the interim analysis was to support the COVID dataset. It's quite reasonable that any licencee(s) may also want to know what that data looks like. Think they had dosed 109 out of 120 patients so they'll likely it'll get the full analysis.
Is the interim analysis going to be statistical or qualitative. I understand the trial is on going hence the term interim.
Thevaim is to inform the covid result - that could be a simple there are no data that counteract that result. Fine balance. Just hope that COPD trial was overpowered on primary efficacy variable
Nolupus - completely agree - from a financial investment perspective its the COPD therapy, with a recurring and embedded value attached to it, that justifies a high multiple in any deal....Covid is a (big) bonus for any acquirer though will add to the multiple of course.
The risk I admire was spending 5 million quid on manufacturing an untested drug for a new disease in case it worked.
Obviously a rational decision and not like there was a lack of cash or interest, still very proud of the company for it.
ChrisTOffer,
I still believe that the real reason for doing the interim readout in COPD was to further the partnership negotiations as well as COvid data ....
Won't be long now to find out who will Synairgen be signing with , imo
Nolupus, what's your take on the COPD readout delay? I remember very early July you seeming like you were jumping ship due to the lateness then...
I agree Chris that the timing seems intentional, I just didn't think it was acceptable to curate the results timeline as you like?!
Thanks Nolupus! I agree and it's almost like the timing is intentional!
When one places themselves in Richard's shoes a couple of months ago well
Can one really believe that he took the risk of doing the interim analysis in COPD without having asile inclinaisons on the positive outcome of the results ??
No way , José. Says I :-)